Cell therapy commercialization

Cell therapy commercialization

‘Cells as therapies’ is a major step change in healthcare. Living cells offer solutions for a range of currently incurable medical conditions; however, both the technology and its essential infrastructure are far from market ready. Despite the limitations of any fledgling technology, the global cell...

Bibliográfalaš dieđut
Váldodahkkit:	Brindley, D, Mason, C
Materiálatiipa:	Book section
Almmustuhtton:	Elsevier 2014

Geahča maid

Cell therapy commercialization: An assessment of translational barriers
Dahkki: Pettitt, D, et al.
Almmustuhtton: (2016)

Commercial Scale Manufacturing of Allogeneic Cell Therapy
Dahkki: Gary M. Pigeau, et al.
Almmustuhtton: (2018-08-01)

Variation in Medicaid and commercial coverage of cell and gene therapies
Dahkki: Molly T. Beinfeld, et al.
Almmustuhtton: (2023-12-01)

An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocol
Dahkki: Pettitt, D, et al.
Almmustuhtton: (2017)

Bioprocessing automation in cell therapy manufacturing: Outcomes of special interest group automation workshop
Dahkki: Ball, O, et al.
Almmustuhtton: (2018)

Expanding the reach of commercial cell therapies requires changes at medical centers
Dahkki: David F. Stroncek, et al.
Almmustuhtton: (2024-02-01)

Impact of fast-track regulatory designations on strategic commercialization decisions for autologous cell therapies
Dahkki: Lam, C, et al.
Almmustuhtton: (2022)

An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocol
Dahkki: Pettitt, David, et al.
Almmustuhtton: (2017)

An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocol
Dahkki: David Pettitt, et al.
Almmustuhtton: (2017-06-01)

Imagining the future of cell therapies: clinical trials, innovation and the intersection of clinical-academic and commercial visions
Dahkki: Ruchi Higham
Almmustuhtton: (2019-10-01)

Effects of different commercial solutions in therapy of hypovolemia in dogs
Dahkki: Stepanović Predrag
Almmustuhtton: (2005-01-01)

Commercializing the stem cell sciences /
Dahkki: Harvey, Olivia
Almmustuhtton: (2012)

Optimising the quality and effectiveness of risk: benefit appraisal methodologies utilised in randomised control trials
Dahkki: Brindley, D, et al.
Almmustuhtton: (2015)

Organic solar cells—the path to commercial success
Dahkki: Riede, M, et al.
Almmustuhtton: (2020)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
Dahkki: Roa Alsajjan, et al.
Almmustuhtton: (2023-09-01)

The potential commercialization of neuronal replacement therapy using smart polymers
Dahkki: Dutt, Anindita, 1971-
Almmustuhtton: (2006)

The issues on the commercialization of perovskite solar cells
Dahkki: Lixiu Zhang, et al.
Almmustuhtton: (2024-01-01)

Review of Commercial Cells For Space Applications
Dahkki: Buckle Rachel, et al.
Almmustuhtton: (2017-01-01)

Strategic analysis of technical, commercial, and regulatory influences on the commercialization of hydrogen fuel cell vehicles
Dahkki: Millard, David A. (David Anthony)
Almmustuhtton: (2016)

Women on commercial farms
Dahkki: O Thompson, et al.
Almmustuhtton: (1985-05-01)

Systematic review protocol: an assessment of the post-approval challenges of autologous CAR-T therapy delivery
Dahkki: Lam, C, et al.
Almmustuhtton: (2019)

Transforming Commercial Copper Sulfide into Injectable Hydrogels for Local Photothermal Therapy
Dahkki: Xiaoran Wang, et al.
Almmustuhtton: (2022-05-01)

Efficacy of a commercially available multi-herbal formulation in periodontal therapy
Dahkki: A Suchetha, et al.
Almmustuhtton: (2013-01-01)

Evaluation of commercially available biodegradable tetracycline fiber therapy in chronic periodontitis
Dahkki: Surinder Sachdeva, et al.
Almmustuhtton: (2011-01-01)

Evolutions in Commercial Meat Poultry Breeding
Dahkki: Anne-Marie Neeteson, et al.
Almmustuhtton: (2023-10-01)

Regulatory considerations for gene therapy products in the US, EU, and Japan
Dahkki: Halioua-Haubold, C, et al.
Almmustuhtton: (2017)

Scalable purification of viral vectors for gene therapy: An appraisal of downstream processing approaches
Dahkki: Fuerstenau-Sharp, M, et al.
Almmustuhtton: (2017)

Cell culture media: An active pharmaceutical ingredient or ancillary material?
Dahkki: Alturkistani, A, et al.
Almmustuhtton: (2018)

Degradation Diagnostics for Commercial Lithium-Ion Cells Tested at −10◦C
Dahkki: Birkl, C, et al.
Almmustuhtton: (2017)

Commercial building /
Dahkki: 380651 Mullin, Ray C.
Almmustuhtton: (1977)

Commercial building /
Dahkki: 380651 Mullin, Ray C.
Almmustuhtton: (1987)

Commercial satellite communication /
Dahkki: 423803 Pascall, Stephan C., et al.
Almmustuhtton: (1997)

Commercial nanoparticles for stem cell labeling and tracking
Dahkki: Wang, Yaqi, et al.
Almmustuhtton: (2013)

Fuel cell technology : reaching towards commercialization /
Dahkki: Sammes, Nigel M.
Almmustuhtton: (2006)

An analysis of the UK’s commercial stem cell clinics
Dahkki: Megan Smith, et al.
Almmustuhtton: (2024-02-01)

Comparative study of commercial crystalline solar cells
Dahkki: Ajit Singh, et al.
Almmustuhtton: (2023-05-01)

Techno-Economic Challenges of Fuel Cell Commercialization
Dahkki: Junye Wang, et al.
Almmustuhtton: (2018-06-01)

A dual variable Markov model to assess the potential benefits of choroideremia gene therapy on quality adjusted life years (QALYs)
Dahkki: Halioua-Haubold, C, et al.
Almmustuhtton: (2018)

Myocarditis in Patients Starting Combination Checkpoint Inhibitor Therapy: Analysis of a Commercial Claims Database
Dahkki: Alistair C. Lindsay, et al.
Almmustuhtton: (2025-01-01)

Commercial prospects for gene therapy and the newly emerging human gene estate industry
Dahkki: Summers, Nevin M. (Nevin Morris)
Almmustuhtton: (2005)